An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial
Liver International · 2024
DOI: 10.1111/liv.15899 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Liver International, 2024. Verfasst von Ang Huang und 22 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: PLA General Hospital Youth Independent Innovation Science Fund project, 302 Hospital Foundation, Beijing Nova Program.
Abstract (Originalsprache)
Background and Aims The use of corticosteroids in chronic drug‐induced liver injury (DILI) is an important issue. Our previous randomized controlled trial showed that patients with chronic DILI benefited from a 48‐week steroid stepwise reduction (SSR) regimen. However, it remains unclear whether a shorter course of therapy can achieve similar efficacy. In this study, we aimed to assess whether a 36‐week SSR can achieve efficacy similar to that of 48‐week SSR.
Methods
A randomized open‐label trial was performed. Eligible patients were randomly assigned to the 36‐ or 48‐week (1:1) SSR group. Liver biopsies were performed at baseline and at the end of treatment. The primary outcome was the proportion of patients with relapse rate (RR). The secondary outcomes were improvement in liver histology and safety.
Results
Of the 90 participants enrolled, 84 (87.5%) completed the trial, and 62 patients (68.9%) were women. Hepatocellular damage was observed in 53.4% of the cohort. The RR was 7.1% in the 36‐week SSR group but 4.8% in the 48‐week SSR group, as determined by per‐protocol set analysis ( p = 1.000). Significant histological improvements in histological activity (93.1% vs. 92.9%, p = 1.000) and fibrosis (41.4% vs. 46.4%, p = .701) were observed in both the groups. Biochemical normalization time did not differ between the two groups. No severe adverse events were observed.
Conclusions
Both the 36‐ and 48‐week SSR regimens demonstrated similar biochemical response and histological improvements with good safety, supporting 36‐week SSR as a preferable therapeutic choice ( ClinicalTrials.gov , NCT03266146).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Senior Department of Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
- Department of Gastroenterology and Hepatology, the First Medical Center of PLA General Hospital, Beijing, China.
- Department of Pathology and Hepatology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
- Peking University 302 Clinical Medical School, Beijing, China.
- Epidemiology Department, the Fifth Medical Center of PLA General Hospital, Beijing, China.
- Department of Gastroenterology, Hainan Hospital of Chinese PLA General Hospital, Hainan, China.
ORCID-Profile: Bin-Xia Chang, Jiang-Tao Liu, Xing-Ran Zhai, Guruprasad P Aithal, Dong Ji, Jingmin Zhao, Zhengsheng Zou
Förderung
- PLA General Hospital Youth Independent Innovation Science Fund project
- 302 Hospital Foundation
- Beijing Nova Program
- Capital Clinical Characteristic Application Research of Beijing Municipal Science and Technology Commission
- Beijing Natural Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Huang, A., Zhu, Y., Liu, S., Sun, Y., Liu, Z., Liang, Q. S., Zhao, J., Chang, B. X., Bi, J. F., Liu, J. T., Zhai, X. R., Xie, H., Li, N., Tian, H., Han, L., Zhuang, Y., Ma, H., Teng, G. J., Zhang, W., …, & Zou, Z. (2024). An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial. Liver International. https://doi.org/10.1111/liv.15899
Vancouver
Huang A, Zhu Y, Liu S, Sun Y, Liu Z, Liang QS, et al. An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial. Liver International. 2024. doi:10.1111/liv.15899
BibTeX
@article{Huang2024,
author = {Huang, Ang and Zhu, Yun and Liu, Shuhong and Sun, Ying and Liu, Zherui and Liang, Qing-Sheng and Zhao, Jun and Chang, Bin-Xia and Bi, Jing-Feng and Liu, Jiang-Tao and Zhai, Xing-Ran and Xie, Huan and Li, Ning and Tian, Hui and Han, Lin and Zhuang, Yingjie and Ma, Hongbin and Teng, Guang-Ju and Zhang, Wei and Aithal, Guruprasad P and Ji, Dong and Zhao, Jingmin and Zou, Zhengsheng},
title = {An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15899}
}
EUVIMED